Thematic Exposure -- 7/10
Align is the originator and global #1 in clear aligners with >70% share -- a near-monopoly at the premium tier.
Theme is secularly growing (clear aligners taking share from metal braces, mid-teens+ CAGR, TAM $5-11B today
→ $20-35B+ by 2030s). Oligopoly hard gate PASS. Held from 8-10 because ALGN's own clear-aligner revenue
was flat in FY2025 (+0.5%) despite double-digit category growth -- low-cost Chinese competition captures
incremental growth and pricing power is eroding. Scanner segment is contested (<30% share).
Weight: 35%
Clear Aligners (Invisalign) -- >70% Global Share
Near-Monopoly -- Brand-As-Verb -- Premium Tier Leader
Invisalign is the category-defining brand with >70% global clear-aligner share. No single rival approaches
15% at the premium tier. Two-sided lock-in: doctors trained on ClinCheck treatment planning + patients
requesting "Invisalign" by name. Largest clinical dataset. 600M+ GP-channel patients vs 22M annual
orthodontic case starts = massive untapped TAM.
Imaging Systems & Services (iTero)
Co-Leading Scanner -- Workflow Lock-In -- But Contested Market
iTero intraoral scanners (20% of revenue) create workflow lock-in with Invisalign. Align is top-3 alongside
3Shape and Dentsply. But combined top-3 only ~55% share, and open-architecture scanners (Medit, Shining 3D)
undercut on price. Not a second oligopoly leg.
| Metric | FY2025 | YoY |
|---|---|---|
| Systems & Services Revenue | $790M | +2.7% |
The Commoditization Risk
The biggest thematic risk: low-cost Chinese players (Angel Aligner/Angelalign, Smartee, Huayu) are capturing
incremental category growth. ALGN's clear-aligner revenue was flat (+0.5% FY25) while the category grew
double-digits. ASPs guided down 1-2% on product/geographic mix. Management calls China "the most competitive
market in the world." The risk is not losing #1 but the category economics drifting toward a price war.
Competitive Moat
| Dimension | Assessment |
|---|---|
| Durability | Two-sided lock-in (doctor training + patient brand pull), largest clinical dataset, iTero hardware-to-software flywheel |
| Buyers | Orthodontists and GP/cosmetic dentists |
| Replacement Risk | Not a technology substitute -- the threat is commoditization from below. A practice can add cheaper brands alongside but ripping out Invisalign+iTero workflow is costly |
| Pricing Power | Price-setter at premium tier, but increasingly price-taker at margin (ASPs guided down 1-2%) |
| Oligopoly Hard Gate | PASS -- >70% share, no rival near 15% |
Data sourced from Daloopa, Align Technology earnings calls, and third-party market research as of June 2026.